460747-44-8

Usage

Uses

Used in Pharmaceutical Industry:
Benzamide, 4-hydroxy-N-methoxy-N-methylis used as an analgesic and anti-inflammatory agent due to its potential therapeutic properties. Its ability to alleviate pain and reduce inflammation makes it a valuable compound for the development of medications targeting various conditions.
Used in Organic Synthesis:
In the field of organic synthesis, Benzamide, 4-hydroxy-N-methoxy-N-methylserves as a key intermediate or building block for the synthesis of more complex organic molecules. Its unique functional groups allow for further chemical reactions, making it a versatile component in the creation of new compounds.
Used in Medicinal Chemistry:
Benzamide, 4-hydroxy-N-methoxy-N-methylis also utilized in medicinal chemistry for the design and development of new drugs. Its structural features can be modified to optimize pharmacological properties, such as potency, selectivity, and bioavailability, leading to the discovery of novel therapeutic agents.

Upstream product

• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 99-96-7 4-hydroxy-benzoic acid 
• 201230-82-2 carbon monoxide 
• 540-38-5 p-Iodophenol 
• 1117-97-1 N,0-dimethylhydroxylamine 
• 56442-22-9 benzyl 4-benzyloxybenzoate 
• 1486-51-7 p-(benzyloxy)benzoic acid 
• 1486-50-6 4-(benzyloxy)benzoic acid chloride 
• 252199-28-3 4-(benzyloxy)-N-methoxy-N-methylbenzamide 

Downstream Products

• 460747-45-9 4-hydroxy-3-iodo-N-methoxy-N-methylbenzamide 
• 643094-45-5 4-{[tert-butyl(dimethyl)silyl]oxy}-N-methoxy-N-methyl benzamide 
• 1227068-54-3 4-(3-chloropyrazin-2-yloxy)-N-methoxy-N-methylbenzenamide 
• 264883-48-9 N-Methoxy-N-methyl-4-[2-(1-pyrrolidinyl)ethoxy]-benzamide 

Relevant academic research and scientific papers

An Efficient synthesis of Weinreb amides and ketones via palladium nanoparticles on ZIF-8 catalysed carbonylative coupling

Heterogeneously catalysed carbonylative coupling reactions such as aminocarbonylation and Suzuki-carbonylation are reported using Pd nanoparticles supported on ZIF-8 for efficient and environmentally attractive synthesis of Weinreb amides and ketones from aryl bromides or iodides. The catalyst is air stable, offers high activity with very low palladium leaching and is recyclable. The presence of a phosphine ligand was required when aryl bromides were used as substrates, while no ligand was necessary when aryl iodides were used. the Partner Organisations 2014.

Diaryldiamines with dual inhibition of the histamine H3 receptor and the norepinephrine transporter and the efficacy of 4-(3-(methylamino)-1- phenylpropyl)-6-(2-(pyrrolidin-1-yl)ethoxy)naphthalen-1-ol in pain

A series of compounds was designed as dual inhibitors of the H3 receptor and the norepinephrine transporter. Compound 5 (rNET Ki = 14 nM; rH3R Ki = 37 nM) was found to be efficacious in a rat model of osteoarthritic pain.

PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS

Pyrazine compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.

Discovery of a novel series of biphenyl benzoic acid derivatives as potent and selective human β3-adrenergic receptor agonists with good oral bioavailability. Part I

A novel class of biphenyl analogues containing a benzoic acid moiety based on lead compound 8i have been identified as potent and selective human β3 adrenergic receptor (β3-AR) agonists with good oral bioavailability and long plasma half-life. After further substituent effects were investigated at the terminal phenyl ring of lead compound 8i, we have discovered that more lipophilic substitution at the R position improved potency and selectivity. As a result of these studies, 10a and 10e were identified as the leading candidates with the best balance of potency, selectivity, and pharmacokinetic profiles. In addition, compounds 10a and 10e were evaluated to be efficacious for a carbachol-induced increase of intravesical pressure, such as an overactive bladder model in anesthetized dogs. This represents the first demonstrated result dealing with β3- AR agonists.

4-(2-[2-(2(R)-Methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention

H3 receptor antagonists based on a 2-aminoethylbenzofuran skeleton have been discovered, which are potent in vitro at human and rat H 3 receptors, with Ki values of 0.1-5.8 nM. Analogues were discovered with potent (0.01-1 mg/kg) cognition and attention enhancing properties in animal models. One compound in particular, 4-(2-[2-(2(R)- methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile (ABT-239), combined potent and selective H3 receptor antagonism and excellent pharmacokinetic and metabolic properties across species, with full efficacy in two behavioral models: a five-trial inhibitory avoidance acquisition model in rat pups at 0.1 mg/kg and a social recognition memory model in adult rats at 0.01 mg/kg. Furthermore, this compound did not stimulate locomotor activity and showed high selectivity for the induction of behavioral efficacy versus central nervous system based side effects. The potency and selectivity of this compound and of analogues from this class support the potential of H3 receptor antagonists for the treatment of cognitive dysfunction.

Structure - Activity relationships of non-imidazole H3 receptor ligands. Part 1

SAR studies for novel non-imidazole containing H3 receptor antagonists with high potency and selectivity for rat H3 receptors are described. A high throughput screening lead, A-923, was further elaborated in a systematic manner to clarify a pharmacophore for this class of aryloxyalkyl piperazine based compounds.

Novel amines as histamine-3 receptor ligands and their therapeutic applications

Compounds of formula (I) or a pharmaceutically acceptable salts or prodrug thereof which are useful for the modulation of the histamine-3 receptors in mammals and which are useful for the treatment of disorders ameliorated by histamine-3 receptor ligands.

Novel amines as histamine-3 receptor ligands and their therapeutic applications

Compounds of formula (I) or a pharmaceutically acceptable salts or prodrug thereof which are useful for the modulation of the histamine-3 receptors in mammals and which are useful for the treatment of disorders ameliorated by histamine-3 receptor ligands.